Top

Published in:

01-01-2011 | Correspondence

The Authors’ Reply

Authors: Zaheer-Ud-Din Babar, Shane Scahill

Published in: PharmacoEconomics | Issue 1/2011

Excerpt

We thank Shafie and Hassali[1] for responding to our article.[2] We aim to open the dialogue and debate around the use of pharmacoeconomics in the developing world through commentary; however, we do not accept that our commentary is conceptually “flawed” or inappropriately referenced. We address the issues we think have been raised by their letter and defend the tenets of our commentary. …

Shafie AA, Hassali MA. Is there a role for pharmacoeconomics in developing countries? [letter]. Pharmacoeconomics 2011; 29 (1): 83–4CrossRefPubMed

Babar ZU, Scahill S. Is there a role for pharmacoeconomics in developing countries? Pharmacoeconomics 2010; 28 (12): 1069–74CrossRefPubMed

How to develop and implement a national drug policy. 2nd ed. Geneva: WHO, 2001 [online]. Available from URL: http://apps.who.int/medicinedocs/pdf/s2283e/s2283e.pdf [Accessed 2010 Aug 28]

Sultanate of Oman; Ministry of Health; The Directorate General of Pharmaceutical Affairs and Drug Control. Oman national drug policy: aims, present situation and future policy recommendations. 2000 Jul 4 [online]. Available from URL: http://www.moh.gov.om/pharma/ndpeng.pdf [Accessed 2010 Nov 4]

Health Action International. Medicine prices, availability, affordability and price components [online]. Available from URL: http://www.haiweb.org/medicineprices/survey_results.php [Accessed 2010 Aug 29]

Cameron A, Ewen M, Degnan DR, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 2009; 373 (9659): 240–9CrossRefPubMed

Babar ZU, Ibrahim MI, Singh H, et al. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med 2007; 4 (3): e82CrossRef

University Sains Malaysia. Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Pharmacoeconomics, Undergraduate course. Penang [online]. Available from URL: http://www.usm.my/dsap/undergrad.asp [Accessed 2010 Aug 24]

Hameed A. Pharmacoeconomics and outcome research in Pakistan [online]. Available from URL: http://www.ispor.org/conferences/shanghai0306/pdf/07-Pakistan-Hameed.pdf [Accessed 2010 Aug 20]

10.

The Network for Consumer Protection. Prices, availability and affordability of medicines in Pakistan. Islamabad: The Network for Consumer Protection, 2006 Aug [online]. Available from URL: http://www.haiweb.org/medicineprices/surveys/200407PK/survey_report.pdf [Accessed 2010 Aug 19]

11.

Tarn YH, Hu S, Kamae I, et al. Health-care systems and pharmacoeconomic research in Asia-Pacific region. Value Health 2008 Mar; 11 Suppl. 1: S137–55CrossRef

12.

Aljunid SM. Pharmacoeconomics and outcome research in Malaysia. 2nd Asia Pacific ISPOR Conference; 2005 Mar 6; Shanghai [online]. Available from URL: http://www.ispor.org/conferences/shanghai0306/pdf/08-Malaysia-Aljunid.pdf [Accessed 2010 Nov 16]

13.

Yamada T, Chen CC, Yamada T, et al. Pharmaceutical price control policy, pharmaceutical innovation, and health durability. Open Pharmacoeconomics Health Econ J 2010; 2: 34–46 [online]. Available from URL: http://www.bentham.org/open/topharmej/articles/V002/34TOPHARMEJ.pdf [Accessed 2010 Nov 16]

14.

Sood N, de Vries H, Gutierrez I, et al. The effect of regulation on pharmaceutical revenues: experience in nineteen countries. Health Aff (Millwood) 2009 Jan-Feb; 28 (1): w125–37CrossRef

15.

Babar ZU, Izham M, Ibrahim M, et al. Development of pharmaceutical industry, innovation and public health: case studies from Malaysia and Pakistan. Pharmaceutical Policy Conference; 2007 Sep 19–21; Zeist

16.

Oortwijn W, Mathijssen J, Banta D. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries. Health Policy 2010; 95: 174–84CrossRefPubMed

Title: The Authors’ Reply
Authors: Zaheer-Ud-Din Babar
Shane Scahill
Publication date: 01-01-2011
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 1/2011
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.2165/11585510-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Authors’ Reply

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2011

Calibrating Models in Economic Evaluation

Availability of and Access to Orphan Drugs

Is There a Role for Pharmacoeconomics in Developing Countries?

Effects of Reference Pricing in Pharmaceutical Markets

Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis

Calibrating Models in Economic Evaluation